In an abortion-prone mouse pregnancy model, oral AZD3965 at 50 mg/kg twice daily from E5.5 to E10.5 reduced embryo resorption versus PBS-treated AP controls (p < 0.001). The tested 25 and 100 mg/kg groups did not establish a significant resorption benefit in the reported comparisons; a monotonic dose response was not demonstrated. [3]
In Long Evans rats, AZD3965 at 1,000 mg/kg by oral gavage once daily for four days decreased visual acuity. Acuity recovered to pre-dose levels seven days after dosing stopped. This adverse functional response limits general safety interpretations of preclinical efficacy findings. [4]
Embryo resorption in an abortion-prone mouse model
Animal study · Normal and abortion-prone mouse pregnancies; 6–8-week-old breeding mice [3]
The moderate AZD3965 dose reduced embryo resorption in AP mice. Low and high doses did not have a significant resorption benefit established by the reported comparisons.
Conditions shared by the study groups
- Route
- Oral administration (Figure 9A: i.g.)
- Frequency
- Twice daily (bid)
- Treatment course
- E5.5 to E10.5; euthanasia at E10.5
- Vehicle
- PBS used for controls; exact active-drug formulation not separately specified
- Low dose
- Model: Abortion-prone DBA/2 male × CBA/J female pregnancy model
- Reported limits: Per-group n is not individually stated; caption gives n = 5–8 for resorption.
- Moderate dose
- Model: Abortion-prone DBA/2 male × CBA/J female pregnancy model
- Reported limits: Per-group n is not individually stated; caption gives n = 5–8 for resorption.
- High dose
- Model: Abortion-prone DBA/2 male × CBA/J female pregnancy model
- Reported limits: Per-group n is not individually stated; caption gives n = 5–8 for resorption.
Methods and source locations
Compound reported in the paper: AZD3965; Compound label in the paper: A14186 (reported catalog number)
Results apply to the paper-reported material and model; no analytical equivalence or current Adooq lot validation is established.
Materials and Methods: Animals and Statistical analyses; Results: Blockade of LA intake with AZD3965; Figure 9A-E
Embryo resorption rate: resorptions / (formed fetuses + resorptions) × 100%: Macroscopic classification by smaller size/darker appearance. Multigroup comparisons: one-way ANOVA; no exact percentages inferred from plot. — Figure 9B-C and caption; Animals; Statistical analyses; final Results paragraph
Low dose · Materials and Methods: Animals and Statistical analyses; Results: Blockade of LA intake with AZD3965; Figure 9A-E
Moderate dose · Materials and Methods: Animals and Statistical analyses; Results: Blockade of LA intake with AZD3965; Figure 9A-E
High dose · Materials and Methods: Animals and Statistical analyses; Results: Blockade of LA intake with AZD3965; Figure 9A-E
Repeat-dose visual acuity and recovery
Animal study · Long Evans hooded rats, 7–9 weeks old; five males and five females per group [4]
High-dose AZD3965 caused a reversible decrease in visual acuity under the tested four-day regimen.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Once daily
- Treatment course
- 4 days; recovery observations through day 11
- Vehicle
- Water with 0.5% w/v hydroxypropyl methylcellulose and 0.1% w/v Tween 80
- AZD3965 repeat dosing
- Model: Long Evans hooded rats; five males and five females per group
- Reported limits: Day 5 used five treated males only and compared with vehicle data from the preceding day.
Methods and source locations
Compound reported in the paper: AZD3965
Results apply to the paper-reported material and model; no analytical equivalence or current Adooq lot validation is established.
Figure 3 and caption; Results 3.2; Methods 2.2-2.4, 2.7, 2.9-2.10
Visual acuity by optomotor reflex: OptoMotry maximum resolvable grating frequency; measurements 1 h post-dose on days 1 and 4, followed by recovery measurements. Standard error bars; repeated-measures random-effects model with animal random effect; one-sided treatment comparisons without multiple-testing adjustment. — Figure 3 caption; Results 3.2; Methods 2.4 and 2.10
AZD3965 repeat dosing · Figure 3 and caption; Results 3.2; Methods 2.2-2.4, 2.7, 2.9-2.10